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Abstract 
Sanfilippo syndrome is an untreatable form of childhood-onset dementia. Whilst several therapeutic strategies are 
being evaluated in human clinical trials including i.v. delivery of AAV9-based gene therapy, an urgent unmet need 
is the availability of non-invasive, quantitative measures of neurodegeneration. We hypothesise that as part of the 
central nervous system, the retina may provide a window through which to ‘visualise’ degenerative lesions in brain 
and amelioration of them following treatment. This is reliant on the age of onset and the rate of disease progression 
being equivalent in retina and brain. For the first time we have assessed in parallel, the nature, age of onset and rate 
of retinal and brain degeneration in a mouse model of Sanfilippo syndrome. Significant accumulation of heparan 
sulphate and expansion of the endo/lysosomal system was observed in both retina and brain pre-symptomatically 
(by 3 weeks of age). Robust and early activation of micro- and macroglia was also observed in both tissues. There was 
substantial thinning of retina and loss of rod and cone photoreceptors by ~ 12 weeks of age, a time at which cognitive 
symptoms are noted. Intravenous delivery of a clinically relevant AAV9-human sulphamidase vector to neonatal mice 
prevented disease lesion appearance in retina and most areas of brain when assessed 6 weeks later. Collectively, the 
findings highlight the previously unrecognised early and significant involvement of retina in the Sanfilippo disease 
process, lesions that are preventable by neonatal treatment with AAV9-sulphamidase. Critically, our data demonstrate 
for the first time that the advancement of retinal disease parallels that occurring in brain in Sanfilippo syndrome, thus 
retina may provide an easily accessible neural tissue via which brain disease development and its amelioration with 
treatment can be monitored.
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Introduction
The temporal course of neurodegeneration in Sanfili-
ppo syndrome or mucopolysaccharidosis type IIIA (MPS 
IIIA) is manifest by a normal infancy followed by progres-
sive intellectual disability in early childhood and death at 
a median age of 18 years [43]. The most common of four 
subtypes of Sanfilippo syndrome in Australia [28], MPS 
IIIA results from an inherited, recessive mutation in the 
gene encoding the lysosomal exoenzyme sulphamidase 
(SGSH; EC 3.10.1.1), leading to incomplete degradation 
of heparan sulphate (HS), its accumulation in lysosomes 
and initiation of an inflammatory and degenerative cas-
cade predominantly affecting the central nervous system 
(CNS).
Sanfilippo syndrome is presently untreatable, how-
ever several therapeutic approaches are under clinical 
evaluation in patients including but not limited to gene 
replacement [11, 19, 40]. The monitoring of both disease 
progression and therapeutic efficacy however, remains a 
significant obstacle and there is an urgent unmet need for 
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practical, non-invasive, and widely available techniques 
to be developed.
Significant retinal pathology occurs in utero in MPS III 
[6] with inclusions observed in photoreceptor cells, retinal 
ganglion cells and glia in the optic nerve. The electroreti-
nogram (ERG) becomes abnormal in childhood [3, 9, 13, 
27]. Gills and colleagues [13] reported retinal pigmentation, 
impairment of the ERG and night-blindness in two MPS III 
patients. In post-mortem specimens from adults with MPS 
III, vacuolation of the retina is observed, with photorecep-
tor degeneration. Haer-Wigman et  al. [16] found muta-
tions in the gene encoding the lysosomal enzyme defective 
in MPS IIIC (heparan acetyl-CoA: alpha-glucosaminide 
N-acetyltransferase) in six adults with retinitis pigmen-
tosa. Typical cognitive decline was not a clinical feature. 
This finding was recently verified in a cohort of 17 adults 
by Schiff and colleagues [35]. Coupled with the observation 
that retinal dysfunction is a common symptom in cogni-
tively normal patients with later-onset MPS IIIA [29], these 
findings suggest that the retina requires a high level of lyso-
somal enzymes for normal function.
A significant loss of retinal function has been reported 
in MPS III mice as they age [18, 21, 42]. Of note, impair-
ments to the dark-adapted ERG are evident, presump-
tively due to a loss of rod function, with lysosomal storage 
observed in Müller cells, disruption of the retinal pig-
ment epithelium apparent from 4 weeks of age onwards, 
and subsequent photoreceptor degeneration. Tse et  al. 
[42] reported that cone degeneration occurs much later 
in these mice (by 46 weeks of age). Emus with MPS IIIB 
have also been reported to exhibit vacuolisation of retinal 
ganglion cells [31].
Embryologically, the retina and optic nerve are out-
pouchings of brain and are part of CNS. Importantly, the 
retina is the only part of the CNS that can be visualised 
non-invasively. Given that many other neurological dis-
orders exhibit retinal/optic nerve pathology prior to, or 
in conjunction with the onset of brain pathology [1, 24], 
we hypothesised that modern retinal and optic nerve 
imaging modalities may serve as an ideal biomarker both 
of progressive CNS disease in Sanfilippo syndrome and, 
potentially, therapeutic efficacy. The aim of the current 
study was to compare the temporal profiles of retinal and 
brain pathology and in short-term studies, determine the 
ability of a clinically relevant i.v.-delivered gene therapy 
approach to mediate improvements in disease sequelae 
in both neural tissues.
Materials and methods
Approvals
The research protocol was approved by the Institu-
tional Animal Ethics Committee (approvals #1060/12/19 
and #1109/12/21) and the Institutional Biosafety 
Committee (#B144/12/20 and #B149-12-21) prior to 
study commencement.
Mice
Congenic MPS IIIA mice (B6.Cg-Sgshmps3a) were 
obtained from a breeding colony established and main-
tained at the Women’s and Children’s Hospital Network, 
North Adelaide, South Australia, Australia. Congenic 
MPS IIIA mice were also intercrossed with a reporter 
line (Thy1-GFP M-line; [10]), purchased from Jax Mice 
to create MPS IIIA mice in which some retinal ganglion 
cells express green fluorescent protein (GFP).
All mice were group-housed in a constant tempera-
ture/humidity-controlled facility with a 14-h light:10-h 
dark cycle, with food and water ad  libitum. Mice were 
provided with toilet rolls and plastic cups plus nesting 
material for environmental enrichment. All breeding, 
housing and experimental procedures complied with the 
Australian code for the care and use of animals for scien-
tific purposes (8th edition; 2013) and the Association for 
Research in Vision and Ophthalmology (ARVO) state-
ment (2016).
Genotyping for the SGSH mutation was undertaken on 
ear-notch tissue from which DNA was extracted (Ther-
moFisher Scientific), with subsequent PCR and restric-
tion digest analysis performed according to methods in 
[26]. The genotypes of the GFP + mice were determined 
using customised Taqman® XFP genotyping assays 
(Thermofisher Scientific). Forward (5′ GCA CCA CCG 
GCA AGC T 3′) and reverse primers (5′ AGT CGT GCT 
GCT TCA TGT GGT 3′) and allele-specific probes (5′ 
CCA CCC TGA CCT ACG  3′) were utilised. Reactions 
containing 2 × TaqMan® Genotyping Mastermix and 
20 × GFP-FAM primer were aliquoted into MicroAmp® 
fast optical 384-well reaction plates and 1 µL DNA was 
added to each well (5 µL total volume per well). Negative, 
no DNA template controls were included in each assay. 
The plates were sealed with MicroAmp® optical adhesive 
film and amplification performed on a QuantStudio 7 
Flex Real-Time PCR system (Thermofisher Scientifc).
Post‑mortem extraction of tissues
No differences have previously been found in the time of 
onset or rate of disease lesion progression in the brains 
of male or female mice with MPS IIIA, therefore, mice of 
mixed genders were humanely killed at 3, 6, 12, 15, 20, 22 
or 25 weeks of age using asphyxiation with slow-fill  CO2. 
Intra-cardiac perfusion with ice-cold saline was under-
taken then brain, eyes and optic nerves were removed. 
Some brain tissue was dissected into five 2 mm hemi-cor-
onal slices, with slice 1 containing olfactory bulb and the 
rostral aspect of the cerebral cortex and slice 5 contain-
ing cerebellum and brainstem. For mass spectrometry 
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evaluation, the retina was carefully dissected from the 
eyes and both brain and retina were frozen at − 80  °C 
until used.
Brain tissue destined for immunohistochemistry was 
immersion-fixed in 4% paraformaldehyde in PBS for up 
to 1 week. Eyes and optic nerves to be used for immuno-
histochemistry were immersion-fixed in Davidson’s solu-
tion (2-parts 37% formaldehyde, 3-parts 100% ethanol, 
1-part glacial acetic acid and 3-parts water) for 24 h and 
then held in 70% alcohol for processing. Davidson’s solu-
tion is the preferred fixative for whole eyes as it provides 
optimal tissue morphology while avoiding retinal detach-
ment. A separate cohort of eyes was collected for retinal 
whole-mount preparation and was fixed in 4% PFA in 
PBS for 24 h before being placed in 30% sucrose at 4 °C 
until dissected as previously described [8].
To determine the impact of sulphamidase gene replace-
ment on retinal and brain disease lesions, on the day of 
birth, cohorts of MPS IIIA and unaffected mice (n = 5/
group) received an intravenous injection of AAV9-CMV-
hSGSH or AAV9-CMV-GFP (5 × 1011 vg; 10 µL) via the 
superficial temporal vein. A repeat injection was made 
via the tail vein on day 5 of life. Control mice of both gen-
otypes received AAV-CMV-mCherry at this time. This 
sequential injection strategy increases the number of 
(newly emerging) retinal neurons exposed to viral vector 
[5]. Mice were weaned into same-sex groups at 3 weeks 
of age and were humanely killed as above at 6 weeks of 
age. Brain and both eyes were removed, and half of the 
brain and one eye was immersion-fixed in 4% paraform-
aldehyde and Davidson’s fixative, respectively, as above. 
Prior to being frozen at − 80  °C, the remaining brain 
hemisphere was divided into five 2 mm slices as above.
Histology and immunohistochemistry
Tissues were processed routinely into paraffin with 
brains and eyes embedded sagittally, and optic nerves 
longitudinally. Six micron-thick tissue sections were cut 
using a rotary microtome (Leica, Wetzlar, Germany) 
and mounted on glass slides (Superfrost™ Plus, Thermo 
Scientific, USA). Retinae were sectioned in a consistent 
manner to the level of the optic nerve head and brain sec-
tions were taken at approximately 0.48 mm lateral to the 
midline (according to the Mouse Brain Atlas [32]). Oven-
dried sections were deparaffinised in xylene, rinsed in 
two changes of 100% ethanol and gently washed in water. 
Haematoxylin and eosin staining was performed using 
standard methods.
Details of tissue type, antigen retrieval pre-treatment, 
primary antibody/lectin reagents used are outlined in 
Table 1. Biotinylated species-specific secondary antibod-
ies, 1:2000 (Jackson ImmunoResearch Labs), Vectastain 
Elite ABC kit reagents (PK-6100; Vector Laborato-
ries, CA, USA) and the diaminobenzidine (DAB) liquid 
substrate chromagen system (#3468; Dako, Glostrup 
Table 1 Details of primary antibodies used for immunohistochemistry
Primary antibody/Lectin Catalogue number, Source Dilution Tissue type Pre‑treatment
Peanut agglutin lectin (PNA), 
biotinylated
#B-1075, Vector Laboratories, 
California, USA
1:3000 Retina, paraffin sections 20-min microwave, 10 mM citrate 
buffer, pH 6
Mouse anti-rhodopsin #MAB5316; Sigma-Aldrich Pty. 
Ltd. NSW, Australia
1:600 Retina, paraffin sections 15-min microwave, 10 mM 
citrate,2 mM EDTA, 0.5% Tween 
20, pH 6
Rabbit anti-RNA-binding protein 
with multiple splicing (RBPMS),
#ab194213; abcam, Victoria, 
Australia
1:250 Retina, flat mounts None
Goat anti-calretinin #AF5065; R&D Systems Minne-
apolis, MN, USA
1:1500 Retina, paraffin sections 1 mM EDTA, 0.05% Tween 20, 
pH8.0 15-min, microwave
Mouse anti-protein kinase 
C-alpha (PKC-α)
#ab31; abcam, Victoria, Australia 1:2000 Retina, paraffin sections 1 mM EDTA, 0.05% Tween 20, 
pH8.0 15-min, microwave
Mouse anti-calbindin #C9848; Sigma-Aldrich Pty. Ltd. 
NSW, Australia
1:1000 Retina, paraffin sections 1 mM EDTA, 0.05% Tween 20, 
pH8.0 15-min, microwave
Mouse anti-lysosomal integral 
membrane protein 2 (LIMP2)
In-house; Hemsley et. al., 2008 1:500 Retina, paraffin sections 1 mM EDTA, 0.05% Tween 20, 
pH8.0 15-min, microwave
1:800 Brain, paraffin sections Target Retrieval Solution (DAKO), 
10- min microwave
Rabbit anti-glial gibrillary acidic 
protein (GFAP)
#Z033401-2; Agilent (DAKO), 
Santa Clara, CA, USA
1:500 Retina, paraffin sections 1 mM EDTA, 0.05% Tween 20, 
pH8.0 15-min, microwave




#L5391; Sigma-Aldrich Pty. Ltd. 
NSW, Australia
1:60 Brain and retina, paraffin sections 0.05% Trypsin, pH 7.6 15 min @ 
37 °C
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Denmark) were used to amplify and provide chromog-
enic visualisation.
Immunohistochemical staining of brain and ocular tis-
sues was performed according to established methods 
[4, 7]. Briefly, both eye and brain sections were deparaffi-
nized and specific antigen retrieval performed prior to 
blocking of non-specific labelling with 10% normal don-
key serum (NDS) in PBS. Sections were incubated over-
night in primary antibody diluted in 2% NDS, washed in 
PBS and endogenous peroxidases blocked in 0.3% hydro-
gen peroxide. Sections were then incubated at room 
temperature in species-specific biotinylated secondary 
antibody, followed by Vectastain ABC reagent and colour 
detection was achieved by applying DAB.
For lectin histochemistry, sections underwent anti-
gen retrieval and then were incubated in hydrogen per-
oxide followed by peroxidase-conjugated isolectin-B4 
overnight. Colour detection was achieved using DAB. 
Terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) was carried out according to pub-
lished methods [12, 33]. All staining was batched, and all 
analyses were conducted by a user blinded to mouse age, 
genotype, and treatment status. Sections were viewed on 
either an Olympus BX41 (with an Olympus UC50 cam-
era), a BX61 microscope (with a ColourView III camera) 
or a Leica SP8X spectral scanning confocal microscope.
Quantification of retinal thickness
H&E-stained sections were evaluated to determine the 
total thickness of the retina and that of individual retinal 
layers. To ensure inter-animal consistency, measurements 
were taken in two locations: 500  µm from the ciliary 
body (representing “peripheral” retina) and 500  µm 
from the optic nerve head (representing “central” retina). 
Measurements were made on each side of the optic nerve 
head and the mean thickness of the peripheral and cen-
tral retina was calculated. For accuracy, retinal thickness 
measurements were only taken of sections in a perpen-
dicular orientation. Total thickness was measured from 
the retinal ganglion cell layer (RGC) to, but not includ-
ing, the retinal pigmented epithelium (RPE). Other meas-
urements taken were the thickness of the inner plexiform 
layer (IPL), inner nuclear layer (INL), outer plexiform 
layer (OPL), outer nuclear layer (ONL), total photorecep-
tor segment layer (PS), inner segment layer (IS) and outer 
segment layer (OS). All measurements were carried out 
blind to genotype/age.
Quantification of TUNEL and immunohistochemical 
labelling
The number of positively stained cells in a specified 
length of retina or in a given area of brain were either 
counted manually or quantified using threshold analysis. 
The relatively low number of TUNEL-positive nuclei 
were counted along the entire length and thickness 
of retinae. Peanut agglutinin-positive cone inner seg-
ment number were counted in a field of view using a 
40X objective on each side of the central and peripheral 
retina. Calretinin positive amacrine cells were counted 
along 450  µm of retina starting 150  µm from each side 
of the optic nerve head. PKCα-positive bipolar cells were 
counted in the central and peripheral retina, for a total 
length of ~ 225 µm on both sides of the optic nerve head. 
Due to their relatively low number, calbindin-positive 
horizontal cells were counted along almost the entire 
length of retina, starting one field of view from the cili-
ary body to within one field of view from the optic nerve 
head using a 40X objective. Cell counts were expressed 
as number of immuno-positive cells/mm. Threshold 
analysis of LIMP2 and GFAP staining, based on the opti-
cal density of positive immunostaining, is reported as % 
immunoreactivity. Rhodopsin staining was undertaken 
for demonstration of rod outer segment changes however 
no quantification was performed.
Preparation of flat mounts for evaluation of RGC number 
and dendritic arbour
Immunolabelling with RBPMS was carried out on free-
floating retinae, which were incubated in primary anti-
body for 3  days at room temperature, washed in PBS 
with 1% triton-X and then incubated in Alexafluor 
488-labelled anti-rabbit secondary antibody for 1 day at 
4 °C. Following further washing in PBS/triton-X, retinae 
were mounted on glass slides using Vectashield anti-fade 
mounting medium with DAPI (#H-1200, Vector Labo-
ratories, Burlingame, USA) and stored in the dark. Flat 
mounts were evaluated on a confocal microscope (SP8X, 
Leica, Germany) with excitation provided by a 488  nm 
laser with emission captured with 493–569 nm filters for 
the green channel.
The density of RGCs was quantified in retinas taken 
from n = 6 mice/genotype at each of 3, 6, 12 and 20 weeks 
of age. A further n = 3 mice/genotype were aged to 
25 weeks. Using a × 40 objective, confocal z-stacks were 
taken through the RGC layer in three consistent regions 
in both central and peripheral retina. RGCs were counted 
manually using Cell counter available in AnalySIS Lifes-
cience software (version 2.8, build 1235; Olympus Soft 
Imaging Solutions, Germany) and are presented as the 
number of cells/mm2 of retina.
To evaluate RGC dendritic morphology, z-stack images 
of three  GFP+ RGCs per mouse (n = 3 mice/genotype/
age; 3, 6, 12 and 20  weeks old) were obtained using a 
20 × objective to capture the entire dendritic tree. Images 
were imported into Fiji open-source image processing 
software [36] and dendritic morphology was assessed 
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manually using plug-ins. A-type RGCs were identified 
based on morphological characteristics i.e. soma size, 
dendritic field size and the radiating pattern of branch-
ing as previously described [38]. Dendritic tree area was 
measured using the convex polygon tool to connect the 
distal tips of dendrites to form a polygon. Total dendritic 
length was determined using NeuronJ available in Fiji. 
and the total number of branches/nodes was determined 
using Cell counter. All analyses were performed by a user 
blind to mouse genotype and age.
Mass spectrometry to quantitate stored heparan sulphate
Unfixed brain slices, optic nerve and retina were homog-
enised in 0.02 M Tris/0.5 M NaCl, pH 7.4, with HS disac-
charides quantified using a previously published method 
[41]. Peak area ratios were determined using Analyst 
1.6.2 software (ABSciex, Concord, Ontario, Canada), 
expressed per mg of total protein.
Statistics
Data are expressed as mean ± SEM or as individual data 
points. Graphical and analytical exploratory data analyses 
were performed, and patterns assessed. To compare dif-
ferences between unaffected and MPS IIIA mice at each 
time point, an un-paired Student’s t-test with a Welch’s 
correction was utilised. (GraphPad Prism version 8). 
Regression models with continuous scale outcome vari-
ables and time-dependant interaction effects were fitted 
to the data, and residuals analysed to validate the models’ 
distributional assumptions. Multiple comparisons were 
handled with ANOVA and post-hoc Bonferroni correc-
tion. Data were regarded as statistically significant when 
p < 0.05.
Results
Figure  1a–d shows representative photos of H&E-
stained 25  week old unaffected and MPS IIIA mouse 
retinae. Total retinal thickness declined progressively in 
MPS IIIA mice (Fig. 1e). We observed no change in the 
thickness of the IPL (Fig. 1f ) or INL (Fig. 1g) until MPS 
IIIA mice reached 25  weeks of age, however the OPL 
(Fig.  1h) exhibited thinning from 22  weeks of age, and 
the ONL (Fig.  1i) was notably thinner in affected mice 
from ~ 12  weeks of age, a finding replicated when the 
number of photoreceptor cells was counted (Fig.  1j). 
TUNEL-positive, presumptively apoptosing cells were 
observed in the MPS IIIA mouse ONL, from 6 weeks of 
age with the peak period occurring around 12 weeks of 
age. (Fig. 1k–m).
Examining the ONL more closely (Fig. 2a, b) we noted 
fewer outer segments in both regions of retina in MPS 
IIIA mice as early as 6  weeks of age (Fig.  2d). Staining 
of rod photoreceptors with rhodopsin (Fig.  2e–h) and 
cone photoreceptors with peanut agglutinin (Fig.  2i–k) 
confirmed the early loss of both photoreceptor subtypes 
in affected mice. Thickening of the inner segments was 
noted in MPS IIIA mouse c.f. unaffected mouse retina 
(Fig. 2j).
In contrast, there was no significant change in the num-
ber of RBPMS-positive retinal ganglion cells (RGCs) in 
MPS IIIA retina to 25 weeks of age (Fig. 3a–c). The neu-
rons had a soma diameter range of 17.8–31.5 μm and a 
dendritic field diameter ranging from 189.2 to 468.8 μm, 
consistent with previous studies [34, 38]. To determine 
whether more discrete changes were present, we evalu-
ated dendritic complexity (Additional file 1: Fig. S1A, B), 
a measure previously used to assess neuronal responses 
to injury, disease, or environmental conditions [2]. Over-
all, RGCs in the MPS IIIA mouse retina were found to 
retain their characteristic morphology and fine dendritic 
geometry and appeared largely unaffected by the disease 
process at least to 20 weeks of age (Additional file 1: Fig. 
S1C–F). Further, there was no convincing loss of cal-
retinin-positive amacrine cells (Fig.  3d–f) in MPS IIIA 
retina; the number of cells declined in mice of both geno-
types with age. PKC-α-labelled rod bipolar cells (Fig. 3g–
i) and calbindin-positive horizontal cells (Fig.  3j–l) also 
appeared largely resilient to the disease process.
We next quantified HS levels in retina, optic nerve 
and brain (Fig.  4a–c), and to confirm and visualise the 
impact of substrate accumulation, stained the tissues 
with a marker of the late endosome/lysosome compart-
ment (lysosomal integral membrane protein, LIMP 2; 
Fig.  4d–o). Significant and progressive accumulation of 
HS occurred in MPS IIIA mouse retina, optic nerve and 
brain from 3 weeks of age (c.f. levels in unaffected mouse 
tissues). Elevated LIMP 2 expression was also evident in 
retina, optic nerve and brain (staining quantified in the 
visual cortex and superior colliculus; Fig. 4f, i, l, o) from 
3  weeks of age and the amount of immunoreactivity 
increased to 25 weeks of age in MPS IIIA mice.
Amoeboid, isolectin-B4-positive and therefore pre-
sumptively activated microglia were noted in MPS IIIA 
mouse retina and optic nerve, as well as visual cortex 
and superior colliculus from 3 weeks of age, the earliest 
time point evaluated (Fig. 5a–l). A cumulative increase in 
retinal and brain GFAP expression was noted in affected 
mice to 25  weeks of age (Fig.  6a–c, g–l); however, no 
change was observed in optic nerve (Fig. 6d–f).
Brain tissue from MPS IIIA mice exhibits increasing 
numbers of ubiquitin-positive axonal inclusions with 
age [4]. Whilst retina contained exceedingly few ubiqui-
tin-positive structures (data not shown), axons in MPS 
IIIA mouse optic nerve exhibited immunoreactive sphe-
roids that increased in number as the disease progressed 
(Additional file 2: Fig. S2A–C).
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Fig. 1 Evaluation of retinal thickness in three to 25 week old unaffected and MPS IIIA mice. Representative images of haematoxylin and 
eosin-stained retina from 25 week old unaffected and MPS IIIA mice are shown. Photos show central (a, b) and peripheral (c, d) retina. e Total retinal 
thickness, defined as the distance from the ganglion cell layer (GCL) to the photoreceptor segments (PS), was quantified in mice aged 3–25 weeks. 
The thickness of the inner plexiform layer (IPL; f), inner nuclear layer (INL; g) and outer plexiform layer (OPL; h) was determined. The thickness of (i) 
and number of rows of cells in (j) the outer nuclear layer (ONL) is shown. Representative images of TUNEL labelling in 25 week old unaffected (k) 
and MPS IIIA (l) mouse central retina. m Quantification of TUNEL-positive cells in the retina of unaffected and MPS IIIA mice aged three to 25 weeks. 
Scale bar: a–d = 50 µm; k, l = 25 µm. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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For retinal imaging to provide a non-invasive, quanti-
tative method for visualising neurodegenerative changes 
in Sanfilippo syndrome, retinal disease must parallel 
brain disease. When we compared the rate of accumula-
tion of HS (Fig. 7a), the rate of endo/lysosomal expansion 
(Fig. 7b, c), the appearance of activated microglia (Fig. 7d, 
e) or the number of GFAP-reactive macroglia (Fig. 7f, g) 
in MPS IIIA mouse brain to that in retina across the time-
frame of the study, we found little difference between the 
two tissue types. LIMP2 accumulated at a statistically sig-
nificantly slower rate in superior colliculus c.f. retina, but 
there was no difference in the rate of LIMP2 accumula-
tion in visual cortex c.f. retina. Nor was there a difference 
in the rate of development of any of the other disease 
lesions in brain versus retina, with all other slopes found 
to be not significantly different to each other, suggesting 
the rate of disease lesion progression is equivalent in the 
two CNS tissue types.
Finally, given there is currently no effective therapy 
for patients with Sanfilippo syndrome, and any treat-
ment strategy developed needs to be capable of pre-
venting development of both brain and retinal disease 
lesions to afford patients maximum quality of life, we 
examined the short-term efficacy of i.v. delivery of 
AAV9-CMV-hSGSH to MPS IIIA mice at day 0 and 5 
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Fig. 2 Evaluation of the inner and outer segments in three to 25 week old unaffected and MPS IIIA mice. Haematoxylin and eosin-stained retina 
showing the photoreceptor segment (PS) layer (a), magnified in (b) to delineate inner (IS) and outer (OS) segments. Quantification of inner (c) and 
outer (d) segment length in central and peripheral retina. e–h Representative images of rhodopsin immunostaining detailing rod outer segments 
in 6 and 25 week old unaffected and MPS IIIA mouse central retina. Peanut agglutin (PNA)-stained cone segments in 25 week old unaffected (i) and 
MPS IIIA (j) central retina. k Quantification of the number of PNA-stained inner segments. Scale bar; a = 25 µm; b = 5 µm; e–h = 20 µm; i, j = 10 µm. 
Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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between day 0 and day 5 of life, however all other mice 
remained healthy post-injection. Mouse retina (Fig. 8a) 
and brain (Fig.  8b–f ) was evaluated at 6  weeks post-
injection. AAV9-CMV-hSGSH normalised the size of 
the endo/lysosomal compartment in MPS IIIA mouse 
retina and also in some (thalamus, rostral and medial 
aspects of cerebral cortex) but not all (inferior collicu-
lus and brainstem) areas of brain examined and signifi-
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Fig. 3 Evaluation of retinal ganglion cells, amacrine cells, bipolar cells and horizontal cells in three to 25 week old unaffected and MPS IIIA 
mouse retina. Representative images of RBPMS-immunolabelled retinal ganglion cells (a, b), calretinin-immunolabelled amacrine cells (d, e), 
PKCα-immunolabelled rod bipolar cells (g, h) and calbindin-immunolabelled horizontal cells (j, k) are shown. Arrows indicate examples of the cell 
type quantified. Quantification of retinal ganglion cells (c), amacrine cells (f), rod bipolar cells (i) and horizontal cells (l). Scale bar; a, b = 25 µm; d, 
e, g, h, j, k = 50 µm. Data are expressed as mean ± SEM. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, the outer nuclear layer. *p < 0.05, 
**p < 0.01
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Discussion
Our goal was to establish the age at which disease lesions 
first become apparent in Sanfilippo mouse retina and 
brain and compare the rate of disease progression in each 
tissue in order to test the hypothesis that examination of 
the retina will provide insight into brain disease stage. 
In short-term studies, we then determined the ability 
of a clinically-relevant gene therapy approach to medi-
ate improvements in disease sequelae in both neural tis-
sues. Our objective is to ultimately provide a therapeutic 
monitoring strategy in addition to a prognostic tool, for 
children diagnosed with this devastating disorder. Whilst 
a few researchers have evaluated disease lesions in MPS 
III mouse retina, those studies have either started later in 
the disease course (three-plus months of age [21, 42]) or 
were qualitative in nature [18]. None have sought to com-
pare brain and retinal disease with the goal of facilitat-
ing non-invasive evaluation of retina in order to inform 
understanding of brain disease.
For the first time, our study reveals that the age of 
onset and rate of progression of retinal disease in mice 
with MPS IIIA are remarkably similar to those in the 
brain. Both tissues exhibit substantial accumulation 
of heparan sulphate by 3  weeks of age, as determined 
by sensitive mass spectrometry-based measurements. 
HS levels in optic nerve were also elevated at this pre-
symptomatic age. Primary storage of HS led to massive 
expansion of the late endosomal/lysosomal system in 
retina, optic nerve and brain as visualised using LIMP2-
staining. Similarly, the presence of presumptively acti-
vated isolectin-B4-positive microglia with an amoeboid 
morphology was noted in all three tissues in 3-week-
old MPS IIIA mice. These cells remained present to the 
end of the study (mice aged 25  weeks) and were only 
rarely observed in unaffected mouse retina and optic 
nerve. Macrogliosis was observed from ~ 6 weeks of age 
in MPS IIIA mouse retina and brain although curiously, 
not in optic nerve. This may be explained by the fact 
that the optic nerve inherently expresses a high level of 
GFAP—astrocytic processes extend in all directions and 
through all planes of the optic nerve, rendering astro-
gliosis more challenging to quantify. Staining of axons 
in optic nerve with antibodies to ubiquitin revealed the 
appearance of axonal spheroids between 3 and 6 weeks 
of age, an observation that has also been made in brain 
[17]. Thus, the age of onset of disease lesions in MPS 
IIIA mouse retina and brain is the same: ~ 3  weeks of 
age.
Disease lesion progression also occurs in parallel in the 
two structures. This suggests that methods that visualise 
and quantitate any of these lesions in MPS IIIA retina 
could inform clinicians about brain disease progression. 
Similarly, the efficacy of any treatment that is able to 
access retina as well as brain, for example i.v. AAV9-
sulphamidase as examined in the present study, or small 
molecule therapeutics such as anti-inflammatory agents 
e.g. Anakinra; IL-1R inhibitor, which is currently under 
clinical evaluation in Sanfilippo patients (www.clini caltr 
ials.gov; NCT04018755), could ostensibly be visualised 
using non-invasive retinal imaging.
The possibility of using retinal lesions to inform our 
understanding of the degree of brain pathology is receiv-
ing increasing attention from researchers evaluating a 
range of neurodegenerative diseases, most notably Alz-
heimer’s disease (AD). Koronyo-Hamaoui et  al. [22] 
were first to describe the presence of Aβ + plaques in AD 
patient retinae, establishing a curcumin-based imaging 
strategy to facilitate the early diagnosis and prognosis 
of AD patients. This technique has recently been evalu-
ated in humans with this disorder [23]. Tau oligomers are 
also present in retina early in the disease process [30], 
and they are associated with neuroinflammatory cells, a 
phenomenon also noted in brain. Similarly, work on the 
3xTg model of AD indicated that tau tangles in addition 
to Aβ plaques and gliosis occurs in the RGL pre-sympto-
matically and could potentially be used to ‘predict’ brain 
pathology in AD [14].
More recent studies demonstrate that hyperspec-
tral imaging enables brain-relevant disease lesions to be 
evaluated in retina [15]. Changes in retinal reflectance 
spectra were found to correlate with brain Aβ load in 
patients with mild cognitive impairment. Similar obser-
vations were made in 5xFAD mice, suggesting that retinal 
hyperspectral imaging may be a useful tool for predicting 
brain Aβ load [15]. Responding to the rapidly expanding 
body of research linking ocular pathology and AD brain 
lesions, the American Alzheimer’s Association convened 
a ‘think tank’ in mid-2019 aimed at establishing the foun-
dations for population-based detection and monitor-
ing of mild cognitive impairment and AD [37]. Other 
disorders for which retinal imaging is being explored as 
a screening/prognostic tool include Parkinson’s disease 
(See figure on next page.)
Fig. 4 Analysis of endo/lysosomal compartment expansion in unaffected and MPS IIIA mouse retina, optic nerve, and brain. Quantification 
of stored heparan sulphate in the retina (a), optic nerve (b) and whole brain (c) in three to 25 week old mice. Representative images of LIMP2 
immunolabelling in 25 week old unaffected and MPS IIIA mouse retina (d, e), optic nerve (g, h), visual cortex (j, k) and superior colliculus (m, n). 
Quantification of % LIMP2 immunoreactivity in the retina (f), optic nerve (i), visual cortex (l) and superior colliculus (o). Scale bar; d, e, g, h, j, k, m, 
n = 50 µm. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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[20], psychiatric diseases including schizophrenia, bipo-
lar disorder and major depressive disorder [39] and mul-
tiple sclerosis [25].
The second novel outcome of our study is the charac-
terisation of retinal lesions present very early in the MPS 
III disease course, i.e. pre-symptomatically. Other stud-
ies have only evaluated Sanfilippo retina from a sympto-
matic stage onwards (12 + weeks [21, 42]). We observed 
apoptotic (TUNEL-positive) cells and shortening of pho-
toreceptor outer segments in both central and peripheral 
retina from 6 weeks of age, followed by loss of inner seg-
ments and profound, progressive loss of photoreceptor cell 
bodies 12  weeks of age in MPS IIIA mice. Both rod and 
 PNA+-cone photoreceptor cells are impacted. Tools capa-
ble of visualising these very early apoptotic events and/or 
detecting initial loss of outer segments may provide prog-
nostic indicators of the early-onset form of Sanfilippo c.f. 
later-onset disease that manifests in adulthood [29].
Other than photoreceptors, all other neuronal classes in 
the retina, including RGCs, bipolar cells, horizontal cells 





























































































































































Fig. 5 Evaluation of microglial activation in three to 25 week old unaffected and MPS IIIA mouse retina, optic nerve and brain. Representative 
images of isolectin-B4 staining in 25 week old unaffected and MPS IIIA mouse retina (a, b), optic nerve (d, e), visual cortex (g, h) and superior 
colliculus (j, k). Insets show higher-power images of ameboid, presumptively activated microglial cells in MPS IIIA mouse tissues. Scale bar = 50 µm. 
Quantification of activated microglia in the retina (c), optic nerve (f), visual cortex (i) and superior colliculus (l) revealed elevated numbers of 
activated microglia in all tissues in MPS IIIA mice from 3 weeks of age. Data are mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001
Page 12 of 16Beard et al. acta neuropathol commun           (2020) 8:194 
and amacrine cells, appear largely unaffected by the dis-
ease process. These parallels observations made in MPS 
IIIA mouse brain tissue: neither we [4], nor others [44] 
have been able to document neuron loss to very late disease 
stages (9  months of age). Therefore, apart from photore-
ceptors which must be acknowledged to be a highly spe-
cialised class of neuron, all other neurons in the retina and 
brain remain intact throughout the symptomatic stages of 
the disease process. Our observations are compatible with 
those reported in MPS IIIB mice by Heldermon et al. [18], 
who showed visible thinning of the ONL between eight 
and 16 weeks of age, and with those of Intartaglia et al. [21] 
who have recently described ONL thickness reductions and 
loss of photoreceptor outer segments at later stages in MPS 
IIIA mice (~ 6 months of age) and likewise reported mini-



























































































































































Fig. 6 Analysis of GFAP-immunoreactivity in three to 25 week old unaffected and MPS IIIA mouse retina, optic nerve and brain. Representative 
images of GFAP immunolabelling in 25 week old unaffected and MPS IIIA mouse retina (a, b), optic nerve (d, e), visual cortex (g, h) and superior 
colliculus (j, k). Scale bar = 50 µm. Quantification of % GFAP immunoreactivity in the retina (c), optic nerve (f) visual cortex (i) and superior colliculus 
(l) revealed elevated GFAP expression in all MPS IIIA tissues except optic nerve. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Loss of rod photoreceptors presumptively leads to the 
impairments previously noted in the dark-adapted ERG 
in MPS III mice [18, 21, 42]. Impaired or absent scotopic 
responses have also been described in patients with MPS 
III who exhibited night blindness [13]. Abnormalities in 
light-adapted ERGs were not noted in MPS IIIB mice 
aged up to 40  weeks of age [18] but became apparent 
by ~ 1 year [42]. The mechanism underlying photorecep-
tor cell death is at present unknown but may relate to 
impaired autophagosome/lysosome fusion which reduces 
autophagic flux [21].
In conclusion, this is the first study to evaluate the rela-
tionship between retinal and brain disease lesions in an 
animal model of a lysosomal storage disorder. We dem-
onstrate that both retina and brain in Sanfilippo mice 
exhibit disease lesions at a very early disease stage (pre-
symptomatic; 3 weeks of age) and that the rate of disease 
progression is comparable between the two structures. 
This bodes well for utilising non-invasive imaging of 
retina to inform our understanding of the state of brain 
disease. The loss of photoreceptor neurons during early 
disease progression and the possibility of visualising and 
monitoring this using non-invasive techniques may pro-
vide both a prognostic and therapeutic monitoring tool 
for MPS IIIA. At the very least, the early age at which ret-
ina displays disease lesions in Sanfilippo syndrome high-
lights the absolute necessity of directing therapeutics at 
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Fig. 7 Relationship between the age of onset and rate of accumulation of disease lesions in the MPS IIIA mouse brain (squares) and retina (circles). 
Data indicating enlargement of the LIMP2-positive endo/lysosomal compartment (a–c), presence of activated microglia (d, e) and elevated 
expression of GFAP by macroglia (f, g) is shown. The slope of the lines was compared, and p values have been tabulated
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Fig. 8 AAV9-CMV-SGSH (or control vector) was delivered i.v. to mice on each of day 0 and day 5 of life and the impact on substrate accumulation in 
the endo/lysosomal compartment in mouse retina and brain was determined 6 weeks post-injection. % LIMP2 immunoreactivity was evaluated in 
the retina (a), rostral cortex (b), medial cortex (c), thalamus (d), inferior colliculus (e) and brainstem (f). Accumulation of primary substrate (heparan 
sulphate) in brain slice 2, 4 and 5 is shown in g–i). The 2 mm thick brain slice protocol is shown in j. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Additional file 1: Figure S1. A-type retinal ganglion cells in unaffected 
Thy1-GFP (A) and MPS IIIA Thy1-GFP mouse retina (B). Scale bar = 50 μm. 
The complexity of the dendritic tree was determined in GFP-positive RGCs 
in unaffected and MPS IIIA mice aged three, six, 12, and 20 weeks of age. 
We observed no significant difference in dendritic tree area (C), total den-
dritic tree cable length (D), or the total number of branch points or nodes 
(E). Negligible change was observed in soma diameter over the 20 week 
time course (F). Data represent mean ± SEM. *p<0.05.
Additional file 2: Figure S2. Representative images of ubiquitin immuno-
labelling in 25 week old unaffected and MPS IIIA optic nerve are shown 
(A, B). Arrows indicate ubiquitin-positive spheroids. Scale bar = 20 µm. 
(C) Ubiquitin-positive axonal spheroids >5 µm diameter were quantified 
in optic nerve obtained from unaffected and MPS IIIA mice aged 3- to 
25-weeks of age. ****p<0.0001.
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